drugset / Trial / NCT03767751
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory Multiple Myeloma,however, a subset of patients relapse due to the loss of target in tumor cells.Dual Specificity CD38 and BCMA CAR-T cells can recognize and kill the malignant cells through recognition of CD38 or BCMA. This is a phase 1/2 study designed to determine the safety of dual specificity CD38 and BCMA CAR-T cells and the feasibility of making enough to treat patients with relapsed or refractory Multiple Myeloma.
Timeline
- Start
- 2018-12-05
- Primary completion
- 2022-12-05
- Completion
- 2022-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dual Specificity CD38 and BCMA CAR-T Cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Dual Specificity CD38 and BCMA CAR-T Cells | Cell therapy | 5e+06 cells/kg | Intravenous |